Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 28, 2008. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 870,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,272.4311 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.06% of total voting rights).
- Shares in Issue: 5,235,348,732 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's share capital through the cancellation of 870,000 shares purchased on August 28, 2008. This transaction increased the proportion of Treasury shares held by the Company to 9.06% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,235,348,732) for calculating disclosure thresholds under the Financial Services Authority's rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on the total voting rights percentage (9.06%).
- Note that the 870,000 shares purchased were cancelled and are no longer part of the issued share capital.